No Data
No Data
Strategic Divestiture and Financial Flexibility: HLS Therapeutics Inc's Optimistic Buy Rating
Stifel Nicolaus Keeps Their Hold Rating on HLS Therapeutics Inc (HLS)
Stocks in Play: HLS Therapeutics Inc.
New Study Published on the Impact of Pharmaceutical Support Programs on Persistence With Clozapine Treatment
HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance
HLS Therapeutics (HLS.TO) reported a wider first quarter net loss than in the year earlier period as revenue fell. The company has also terminated its agreement with Pfizer. The pharmaceutical compan
Press Release: HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call Canada NewsWire TORONTO, April 25, 2024 TORONTO, April 25, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX